Advertisement

KalVista ends trials of angioedema drug

Oct 4 (Reuters) - KalVista Pharmaceuticals Inc said on Tuesday it has terminated a mid-stage study for its drug to prevent recurrent swelling attacks in people with hereditary angioedema, due to elevated levels of liver enzymes in patients. (Reporting by Khushi Mandowara in Bengaluru; editing by Uttaresh.V)